THE IMMINENT (!?) RETURN OF SKIN TESTING FOR COCCIDIOIDOMYCOSIS: A PRIMER

Elizabeth Wack, MD
(Infectious Disease, Private Practice)
Outline

- Early Work with Coccidioidin
- Coccidioidin vrs Spherulin
- ST Placement and Interpretation
- Epidemiologic Usefulness of the ST
- Clinical Usefulness of the ST
- Development of a new Cocci ST
Charles Smith, MD

- Professor of Public Health at Stanford
- 1937-1939 “wandering epidemiologist of Kern and Tulare County”
- Standardized Cocci ST and serological testing
- Consultant to the Secretary of War during WWII
- 1942 Dean of the School of Public Health at UC, Berkeley

Ref: Stevens, Coccidioidomycosis, A Text, 1980
Coccidioidin - The First Skin Test

- Cooke in 1915 first attempted ST with an emulsion of mycelia and spherules
- Coccidioidin = Culture filtrate of mycelium grown in broth
- Developed and standardized by C. E. Smith and associates in the 1930s
- 1:100 dilution = standard test dose
- 1:10 dilution = optional
- Supplies depleted in approximately 1980
Epidemiologic Studies on Military Personnel in the San Joaquin Valley

- 1940-1941

- Goal: Identify persons who had not been infected before entering the endemic area, determine the extent of illness associated with ST conversion, evaluate the relationship of infection to time of year and climatic conditions

- Provision for the postmortem of persons dying of Cocci
Epidemiologic Studies on Military: Conclusions

- Previous ST positivity was protective against subsequent infection
- Recruits with negative ST were susceptible to pulmonary Cocci; conversions were often asymptomatic; when symptomatic the disease was rarely fatal
- Black soldiers were more likely to disseminate
- The endemicity of Cocci was spotty even in areas of known risk
Epidemiologic Studies on Military: Conclusions, cont

- There was distinct seasonal variation in the infection rate—highest in late summer.
- The more dust, the more ST conversions.
- Less construction, more lawns and paving, less outdoor sports = decrease in new infections by 65%.
- The infection is was not restricted to San Joaquin Valley.

Would a ST antigen prepared from the host-related form provide a superior ST reagent?

First produced by H.B. Levine 1950s

Soluble fraction released by spherules produced in vitro then lysed by incubation in sterile water

Replaced coccidioidin in late 1970s, early 1980s

2 strengths:
- “Usual strength” equal to the 1:100 coccidioidin (2.8ugm)
- “High test strength” equal to the 1:10 coccidioidin (28ugm)
Comparison of Coccidioidin and Spherulin

- Spherulin detects approx one third more persons who have experienced Cocci than coccidioidin
- Subjects who react to coccidioidin will always react to spherulin
- Only rare evidence of cross reactivity between Histo and Cocci
- Both ST are non reactive in patients from outside endemic area or with infections other than Cocci

Ref: Dermal Sensitivity to Coccidioides immitis, Levine, Am Rev Resp Dis, 1973
Method of ST Placement

- Intradermal using short beveled 24-26 gauge needle
- Volar surface of the forearm
- At 48 hours, measure visible and palpable induration
- Induration of 5 mm or more is positive
- Avoid ST placement in patients with erythema nodosum- has caused violent reaction, local necrosis, and exacerbation of the EN

7.5% of 1647 “Anglowhite” subjects exhibited an immediate wheal and flare reaction.

Immediate wheal and flare reaction associated with a higher rate of positive ST reading at 48h.

Reading at 24 hours may lead to a false positive due to immediate hypersensitivity reaction.

Graph of Cocci Serology and ST Conversion - Smith, Ped Clinic N Am, 1955
ST in Primary Pulmonary Cocci

- Positive ST develops within 3 days to 3 weeks after onset of symptoms
- 83% within the first week
- 99% by the third week
- ST does not adversely affect illness, serological testing

Ref: Coccidioidomycosis, Drutz, Am Rev Resp Dis, 1978
Interpretation of a Negative ST

- A negative test suggests the patient has not been infected—as long as the patient does not have a chronic underlying condition that suppresses delayed cutaneous hypersensitivity.

- However, there is a 2-4 week delay between infection and skin positivity.

- ST reactivity may wane with time - Clinical significance not clear.
ST in Disseminated Cocci – a Special Situation

- Usually ST reactivity never develops or wanes coincident with CF increasing
- A ST may be negative in a patient with severe Cocci infection
- Establishment or re establishment of reactivity during treatment or convalescence may be a good prognostic sign

- Ref: Drutz, Am Rev Resp Dis, 1978
Interpretation of a Positive ST

- A robust cellular immune response indicates that Cocci infection has occurred and that the host has developed long lived immunity.

- Some cross reactivity between Cocci ST and histoplasmosis – though endemic areas are almost exclusive - overlapping only in Texas.
Epidemiologic Uses of ST

- ST data provides prevalence data in certain geographic areas
- Knowing the current prevalence of infection in a population helps estimate the number of persons susceptible
- Together with recognition of proven cases and ecologic studies, ST data is used to establish the distribution of *C. Immitis* in nature
Prevalence of Cocci ST in Ambulatory Population- Maricopa County, 1983

- 1020 patients aged 5-74
- Jan to April 1983
- Over all prevalence rate for all ages = 21.5%
- Rate directly related to length of residence in an endemic area
- Marked increase when residence was 5 or greater years

DuQuetee, Coccidioidomycosis, Proceedings of the 4th International Conference, 1984
Prevalence of Cocci ST Sensitivity by Age in Maricopa County, 1983
Clinical Use of Cocci ST

- Documented conversion from negative to positive can be used to help diagnose primary pulmonary Cocci
- A positive ST is protective against second infection
- Therefore, in a host known to be previously ST positive, a new pneumonia is not likely to be Cocci
Clinical Uses of ST, Cont.

- Development of a positive ST in a patient with known pulmonary Cocci is a good prognostic sign.

- Failure to develop a positive ST in a patient with known pulmonary Cocci is a bad prognostic sign and is associated with a higher frequency of relapse when therapy is discontinued.
Development of a new Cocci ST

- Spherulin was originally produced and marketed by Berkley Biologicals.
- Subsequently the product was sold twice and marketing was discontinued in 1990s.
- Since then, the product was purchased by Allermed and a reformulation and testing project was undertaken.
Spherule Derived Coccidioidin (SDC) (Spherusol)

- Newly formatted phenolic preserved spherule derived coccidioidin (SDC) – Studies over the last ten years.

- Ref: Delayed Hypersensitivity Skin Testing for Coccidioidomycosis: The Re-evaluation of Four Studies on the road to a Marketable Test Antigen; R. Johnson, N. M. Ampel, S. Nielsen, S. Kernerman, B. Sawtelle
In individuals with no history of or likely exposure to coccidioidal infections in Spokane, Washington on 59 evaluable patients:
- Only one individual had a 5 mm response.

In a study in Blair, Nebraska, an area endemic for histoplasmosis, on 12 patients:
- All twelve were negative.
In a phase III sensitivity study undertaken in Bakersfield, California and Tucson, Arizona:
- 52/53 reacted positively.
- The adverse event rate was low.
SDC Conclusion

- SDC was demonstrated to have sensitivity, specificity and safety such that it should be available for use in evaluating individuals for Coccidioidomycosis.

- Currently in the hands of the FDA.............(!?)
Outline - Recap

- Early Work with Coccidioidin
- Coccidioidin vrs Spherulin
- ST Placement and Interpretation
- Epidemiologic Usefulness of the ST
- Clinical Usefulness of the ST
- Development of a new Cocci ST

Discussion?